Subscribe to RSS
DOI: 10.1055/s-0030-1267235
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Expression of Matrix-Metalloproteases in the Fluid of Chronic Diabetic Foot Wounds Treated with a Protease Absorbent Dressing
Publication History
received 19.07.2010
first decision 20.09.2010
accepted 27.09.2010
Publication Date:
28 October 2010 (online)
Abstract
It is well known, that wound healing in diabetes is impaired. Persistently high levels of matrix-metalloproteases (MMPs) contribute to wound persistence. The topical use of protease-inhibitors might beneficially affect wound healing.
Research design and methods: 19 patients with chronic diabetic foot lesions (Wagner/Armstrong 2A) were studied. 6 patients received “good standard wound care”, 13 patients were treated with a protease-inhibitor-modulating-matrix (ORC/collagen matrix) that was changed daily. At day 1 and 5 biopsies were taken from the wounds; wound fluids were collected daily. Biopsies were analysed using quantitative real-time-PCR and all samples were analysed using ELISA and zymography for MMPs, TIMPs, IL 1-β and TNFα levels.
Results: No differences in mRNA-expression of MMPs, TNFα and for MMP levels in wound tissue were detected between both groups or between the 2 sampling time points. MMP-2 active was significantly reduced in wound fluids of ORC/collagen treated lesions (p=0.043) after 5 days. MMP-2 pro was also reduced by about 25% when compared to increasing levels in the control group (+27%). We observed a significant reduction of the wound area in the ORC/collagen group (p=0.003).
Conclusions: Local treatment with a protease-inhibitor has a beneficial effect on wound healing. In contrast to unchanged mRNA-levels and protein levels of MMPs there was a clear reduction of MMP-2-levels in wound fluids. Our data support the potential role of ORC/collagen as a wound dressing. Modulation of MMPs appears to be beneficial in the treatment of chronic diabetic wounds.
Key words
diabetic foot syndrome - matrix-metalloproteases - protease absorbent dressing
References
- 1 Boyko EJ, Ahroni JH, Smith DG. et al . Increased mortality associated with diabetic foot ulcers. Diabet Med. 1996; 13 967-972
- 2 Frykberg RG. Diabetic foot ulcerations: management and adjunctive therapy. Clin Podiatr Med Surg. 2003; 20 709-728
- 3 Saar WE, Lee TH, Berlet GC. The economic burden of diabetic foot and ankle disorders. Foot Ankle Int. 2005; 26 27-31
- 4 Ramsey SD, Newton K, Blough D. et al . Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 2001; 22 (3) 382-387
- 5 Lobmann R, Mueller E, Kersken J. et al . The diabetic foot in Germany: Analysis of Quality in specialised diabetic wound care centers. The Diabetic Foot Journal. 2007; 10 68-72
- 6 Heller G, Gunster C, Schellschmidt H. How frequent are diabetes-related amputations of the lower limbs in Germany? An analysis on the basis of routine data. Dtsch Med Wochenschr. 2004; 129 429-433
- 7 Trautner C, Haastert B, Giani G. et al . Amputations and diabetes: a case-control study. Diabet Med. 2002; 19 35-40
- 8 Lobmann R, Ambrosch A, Schultz G. et al . Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia. 2002; 45 1011-1016
- 9 Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2005; 28 461-471
- 10 Mast BA, Schultz GS. Interactions of cytokines, growth factors and proteases in acute and chronic wounds. Wound Repair Regen. 1996; 4 420-441
- 11 Trengove NJ, Stacey MC, MacAuley S. et al . Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999; 7 442-452
- 12 Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen. 1999; 7 433-441
- 13 Claxton MJ, Armstrong DG, Boulton AJ. Healing the diabetic wound and keeping it healed: modalities for the early 21st century. Curr Diab Rep. 2002; 2 510-518
- 14 Nwomeh BC, Yager DR, Cohen IK. Physiology of the chronic wound. Clin Plast Surg. 1998; 25 341-356
- 15 Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005; 366 1736-1743
- 16 Medina A, Scott PG, Ghahary A. et al . Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil. 2005; 26 306-319
- 17 Tomic-Canic M, Brem H. Gene array technology and pathogenesis of chronic wounds. Am J Surg. 2004; 188 67-72
- 18 Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999; 341 738-746
- 19 Doxey DL, Ng MC, Dill RE. et al . Platelet-derived growth factor levels in wounds of diabetic rats. Life Sci. 1995; 57 1111-1123
- 20 Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000; 8 13-25
- 21 Morris EJ, Dowlen S, Cullen B. Early clinical experience with topical collagen in vascular wound care. J Wound Ostomy Continence Nurs. 1994; 21 247-250
- 22 Cullen B, Smith R, McCulloch E. et al . Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen. 2002; 10 16-25
- 23 Cullen B, Watt PW, Lundqvist C. et al . The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol. 2002; 34 1544-1556
- 24 Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in 4 European countries. J Wound Care. 2002; 11 70-74
- 25 Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs. standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002; 137 822-827
- 26 World Medical Association. . Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000; 284 3043-3045
- 27 Shigeyama Y, Pap T, Kunzler P. et al . Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 2000; 43 2523-2530
- 28 Petri JB, König S, Haupt B. et al . Molecular analysis of different phases in human wound healing. Experimental Dermatology. 1997; 6 133-139
- 29 Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen. 1996; 4 321-325
- 30 Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc. 2002; 92 12-18
- 31 Omugha N, Jones AM. The management of hard-to-heal necrobiosis with PROMOGRAN. Br J Nurs. 2003; 12 S14-S20
- 32 Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in 4 European countries. J Wound Care. 2002; 11 70-74
- 33 Vin F, Teot L, Meaume S. The healing properties of promogran in venous leg ulcers. J Wound Care. 2002; 11 335-341
- 34 Hart J, Silcock D, Gunnigle S. et al . The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing. Int J Biochem Cell Biol. 2002; 34 1557-1570
- 35 Lobmann R, Zemlin C, Motzkau M. et al . Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications. 2006; 20 329-335
- 36 Liu Y, Min D, Bolton T. et al . Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care. 2009; 32 (1) 117-119
- 37 Brandner JM, Zacheja S, Houdek P. et al . Expression of matrix metalloproteinases, cytokines, and connexins in diabetic and nondiabetic human keratinocytes before and after transplantation into an ex vivo wound-healing model. Diabetes Care. 2008; 31 (1) 114-120
Correspondence
R. LobmannMD
Department of Endocrinology
Diabetology and Geriatric Medicine
Klinikum Stuttgart –
Bürgerhospital
Tunzhofer Straße 14–16
70191 Stuttgart
Phone: +49/0711/253 2600
Fax: +49/0711/253 2173
Email: R.Lobmann@klinikum-stuttgart.de